Director at Traws Pharma (TRAW) receives grant of 33,435 stock options

Rhea-AI Filing Summary

Traws Pharma director Clarke Trafford received a new stock option grant as part of his compensation. He was awarded options for 33,435 shares of common stock at an exercise price of $1.60 per share. These options were granted under the company’s 2021 Incentive Compensation Plan by the independent compensation committee and will vest 100% on the first anniversary of the March 8, 2026 grant date. Following this award, Trafford holds 33,435 stock options directly, which are scheduled to expire on March 8, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clarke Trafford

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	03/08/2026		A		33,435		03/08/2027(1)	03/08/2036	Common Stock	33,435	$0	33,435	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Trafford Clarke	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Traws Pharma (TRAW) director Clarke Trafford report in this Form 4?

Clarke Trafford reported receiving a grant of stock options for 33,435 Traws Pharma shares. The award is a compensation grant, not an open-market purchase or sale, and reflects equity-based pay approved by the company’s independent compensation committee.

How many Traws Pharma (TRAW) stock options were granted to Clarke Trafford and at what price?

Clarke Trafford was granted options for 33,435 shares of Traws Pharma common stock at an exercise price of $1.60 per share. This means he can choose to buy those shares at $1.60 once the options are vested and exercisable.

When do Clarke Trafford’s new Traws Pharma (TRAW) stock options vest and expire?

The stock options granted to Clarke Trafford will vest 100% on the first anniversary of the grant date, March 8, 2027. They have an expiration date of March 8, 2036, after which any unexercised options will no longer be usable.

Is Clarke Trafford’s Form 4 transaction a market buy or sell of Traws Pharma (TRAW) shares?

The Form 4 reports a grant of stock options as compensation, not a market buy or sell. The transaction code is “A,” indicating a grant or award acquisition, so no cash trade occurred in the open market for this reported transaction.

Who approved the stock option grant to Traws Pharma (TRAW) director Clarke Trafford?

The stock option grant to Clarke Trafford was approved by Traws Pharma’s compensation committee, which is comprised of independent directors. The award was made under the company’s 2021 Incentive Compensation Plan, as amended and restated through the grant date.